Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Overview: The company develops, manufactures, and sells disposable medical connection products, primarily proprietary safe medical connection devices for intravenous (I.V.) therapy. Key products include the CLAVE(R) connector, custom I.V. systems, and protected needle products.
Key Financial Metrics
| Metric (in thousands) | Q3 2002 | Q3 2001 | YTD 9 Months 2002 | YTD 9 Months 2001 |
|---|---|---|---|---|
| Net Sales | $20,105 | $16,214 | $63,678 | $48,172 |
| Gross Profit | $11,564 | $9,347 | $37,249 | $27,957 |
| Gross Margin | 58% | 58% | 58% | 58% |
| Operating Income | $6,437 | $4,819 | $20,818 | $15,195 |
| Net Income | $4,276 | $3,319 | $13,797 | $10,616 |
| Diluted EPS | $0.28 | $0.23 | $0.90 | $0.74 |
| Cash & Liquid Investments | $90,219 | $73,027 | $90,219 | $73,027 |
| Operating Cash Flow (YTD) | N/A | $17,975 | $18,748 | |
| Capital Expenditures (YTD) | ($8,446) | ($4,011) |
Note: All dollar amounts in thousands except per share data. Operating cash flow includes tax benefits from stock option exercises.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 24% in Q3 2002 and 32% YTD compared to the prior year. Growth was driven by a 114% increase in custom and generic I.V. systems sales and an 8% increase in CLAVE product sales.
- Customer Concentration: Abbott Laboratories accounted for 61% of Q3 2002 sales (up from 57% in Q3 2001). Sales to B. Braun Medical Inc. declined significantly (10% of Q3 2002 sales vs. 20% in Q3 2001) due to the termination of their CLAVE supply agreement effective December 31, 2002.
- Inventory Build-up: Inventories increased to $5.3 million from $1.6 million at year-end 2001. This was due to increased raw material stockpiling to meet production schedules and finished goods buildup for anticipated Q4 demand and scheduled maintenance.
- Profitability: Net income rose 29% in Q3 and 30% YTD. Gross margins remained stable at 58% despite price reductions, offset by manufacturing efficiencies and higher volume absorption of overhead.
Guidance, Outlook, and Risks
- Acquisition: On November 13, 2002, the company acquired Bio-Plexus, Inc. for approximately $10 million cash plus $1.2 million debt assumption. Bio-Plexus produces blood collection needles and will be consolidated starting November 1, 2002.
- Capital Expenditures: Management expects 2002 capital expenditures to range between $13 million and $14 million, focused on automation, facility expansion in Mexico, and new enterprise software.
- Outlook: Management expects significant growth in CLAVE and SetSource sales with Abbott in Q4 2002. They anticipate a decline in sales of protected needle products as the market shifts to needleless technology.
- Risks:
- Customer Concentration: Heavy reliance on Abbott (64% of YTD sales) and the loss of B. Braun as a CLAVE customer.
- Legal Proceedings: Ongoing patent infringement litigation against B. Braun regarding their UltraSite product; contract litigation settled with agreement to terminate CLAVE sales.
- Competition: Pressure from competitors developing similar one-piece needleless connectors, leading to downward price pressure.
Investor Verification Checklist
- Customer Dependency: Verify the stability of the Abbott Laboratories agreement and the impact of losing B. Braun as a CLAVE distributor post-December 2002.
- Inventory Levels: Assess the necessity of the $3.7 million inventory increase and the risk of obsolescence if Q4 demand does not materialize.
- Acquisition Integration: Monitor the integration of Bio-Plexus, which reported operating losses of approximately $250,000 per month prior to acquisition.
- Capital Allocation: Track the $13-$14 million capital expenditure plan against actual cash burn and operating cash flow generation.
- Legal Exposure: Follow the status of the patent infringement suit against B. Braun, which could result in damages or injunctions.